T-Cell Europe GmbH

https://www.t-cell.de

The objective of t-cell Europe GmbH (a spin-off of the Berlin-Brandenburg Center for Regenerative Therapies, a joint center of the Charité University Medical Center in Berlin and the Helmholtz Center in Geesthacht which works to translate scientific results into clinical practice) is to develop and commercialize novel T-cell-based therapies based on its IP-protected platform technology. Its first product for a specific medical indication is to be a Treg-cell product for use in conjunction with kidney transplants. t-cell enjoys a strong position which is protected by patents which cannot be circumvented. *

	Start	2010-01-01 splitoff
	Predecessor	Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Campus Teltow
	Industry	cell therapy
	Industry 2	transplantation
	Person	Ulbrich, Claudia (Cardior Therapeutics 201705– CEO before T-Cell Europe GmbH 201205 Managing Director)

	Region	Kleinmachnow
	Country	Germany
	Street	1 Albert-Einstein-Ring
	City	14532 Kleinmachnow
	Tel	+49-33203-1825-75
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-12-30

Picture Berlin Partner Top News New Ariceum Radiopharma Lab 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)